Nurix Therapeutics, Inc.
NRIXNASDAQHealthcare● Active
$15.53
+$0.89(+6.05%)
Market Cap$1.3B
P/E Ratio—
52W High$22.5
52W Low$8.195
Nurix Therapeutics, Inc. (NRIX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NRIX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-11 | 2024-11 | 2023-11 | 2022-11 | 2021-11 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M |
| Cost of Revenue | $18.86M | $221.63M | $189.15M | $184.50M | $116.43M |
| Gross Profit | $65.12M | ($167.08M) | ($112.16M) | ($145.87M) | ($86.68M) |
| Gross Margin %(computed) | 77.55% | -306.30% | -145.69% | -377.64% | -291.37% |
| Operating Expenses | |||||
| R&D Expenses | $308.16M | $221.63M | $189.15M | $184.50M | $116.43M |
| G&A Expenses | $52.74M | $45.94M | $42.90M | $38.00M | $31.20M |
| Total Operating Expenses | $350.79M | $45.94M | $42.90M | $38.00M | $31.20M |
| Operating Income | ($285.67M) | ($213.03M) | ($155.06M) | ($183.87M) | ($117.89M) |
| Operating Margin %(computed) | -340.16% | -390.52% | -201.41% | -476.01% | -396.26% |
| Interest Income | $21.97M | $19.73M | $11.12M | $3.51M | $0.82M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($263.70M) | ($193.30M) | ($143.95M) | ($180.36M) | ($117.06M) |
| Income Tax Expense | $0.76M | $0.27M | $0.00M | $0.00M | $0.13M |
| Net Income | ($264.46M) | ($193.57M) | ($143.95M) | ($180.36M) | ($117.19M) |
| Net Margin %(computed) | -314.90% | -354.85% | -186.98% | -466.93% | -393.93% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 |
| Wtd Avg Shares | 86.67M | 67.12M | 54.34M | 48.61M | 42.90M |
| EBITDA | ($244.84M) | ($205.01M) | ($148.93M) | ($179.72M) | ($115.90M) |
| EBITDA Margin %(computed) | -291.55% | -375.83% | -193.45% | -465.27% | -389.57% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Nurix Therapeutics, Inc. data
About Nurix Therapeutics, Inc. (NRIX) Income Statement
Nurix Therapeutics, Inc. (NRIX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NRIX reported revenue of $0.08B, gross profit of $0.07B (gross margin 77.55%), and net income of ($0.26B) — a net profit margin of -314.90%.
Frequently asked questions
NRIX · 4 questionsNurix Therapeutics, Inc. (NRIX) reported revenue of $0.08B for 2025, up 54.0% year-over-year.
NRIX revenueNRIX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08